indapamide / Generic mfg. - LARVOL DELTA

Dapagliflozin for treatment of sickle cell nephropathy: A multi-centre experience (ASH 2025) - "Thirty-five patients (90%)were receiving disease-modifying therapy for sickle cell disease (23 patients taking hydroxyurea and 12patients on a regular transfusion programme). Six patients were also prescribed anti-hypertensivetherapy (amlodipine, doxazosin or indapamide) and 6 patients were prescribed erythropoietinstimulating agents (ESA).Mean eGFR prior to starting dapagliflozin was 50ml/min/1.73m2 (standard deviation 14ml/min/1.73m2).There was a small reduction in eGFR shortly after commencing dapagliflozin treatment: mean decreaseof 5ml/min/1.73m2 (95% confidence interval 2-7ml/min/1.73m2, P<0.001), evaluated in 36 patients witheGFR measured at least one month (median 4.5months) after starting dapagliflozin...Dapagliflozinappeared generally well tolerated, with a few patients experiencing a recognised complication of urinarytract infections. A small rise in creatinine is expected during initial treatment due to a reduction inintraglomerular pressure caused by..."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Genetic Disorders • Heart Failure • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Sickle Cell Disease • Type 2 Diabetes Mellitus

Cyclodextrin-Based Inclusion Complexes to Enhance the Solubility and Oral Bioavailability of Indapamide: Experimental and Computational Approaches. (PubMed, Drug Dev Ind Pharm) - "The integrated findings highlight the superior potential of modified cyclodextrins, particularly sulfobutylether-β-CD, as excipients for improving solubility, dissolution, and oral bioavailability of indapamide. These results establish a mechanistic foundation for future formulation strategies targeting poorly water-soluble diuretics and related therapeutic agents."

Journal

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Secondary Prevention of Kidney Stones: Randomized, Double-Blind, Crossover Trial (INDAPACHLOR Trial) (KIDNEY WEEK 2025) - P2 | "The NOSTONE trial recently demonstrated that hydrochlorothiazide (HCT) has limited efficacy in preventing recurrence. The study was initially expected to conclude by the end of 2027; however, current recruiting rates indicate it may finish earlier than anticipated. Conclusion No conclusions available — study in progress."

Clinical • Nephrology • Renal Calculi

Polypharmacy Screen of the Thiazide-Sensitive Sodium Chloride Cotransporter (NCC) (KIDNEY WEEK 2025) - "10 compounds were selected for further study: atenolol, furosemide, bendroflumethiazide, dapagliflozin, empagliflozin, labetalol, ramiprilat, metolazone, amlodipine and indapamide. Conclusion Potentially significant interactions between the site of known NCC inhibition and three compounds known to exert diuretic effects (dapagliflozin, empagliflozin and furosemide) have been identified in this computational screening study. A selection of docked conformations from a virtual polypharmacy screen of NCC."

Cardiovascular • Hypertension

A Balancing Act: Prostate Cancer, Antiandrogen Therapy, and Cardiovascular Disease (KIDNEY WEEK 2025) - "Case Description A 70-year-old male with no comorbidities and high risk, localized PCa was initially treated with Bicalutamide followed by radiation. Three years later due to recurrence abiraterone and prednisone was initiated...BP was refractory to five anti-HTN medications (amlodipine, hydralazine, eplerenone, clonidine, indapamide), which were added over time at tolerated doses...Mineralocorticoid receptor antagonists may interfere with Abiraterone's mechanism of action, limiting their role in treating HTN. Thus Timely recognition of PCa therapy-related side effects is essential to minimize cardiovascular mortality and prevent treatment disruption."

Congestive Heart Failure • Genito-urinary Cancer • Heart Failure • Hypertension • Oncology • Prostate Cancer • Solid Tumor

Advance-HTN Trial Participant Characteristics Associated with a Failure to be Randomized (AHA 2025) - "The Advance-HTN trial demonstrated the BP lowering efficacy of lorundrostat compared with placebo. In contrast, use of indapamide in the standardized AHT regimen was associated with greater odds of failing to be randomized (OR: 1.39, 95% CI: 1.03-1.87, p = 0.03).ConclusionAdvance-HTN participant characteristics associated with a failure to be randomized were identified. These data may inform future hypertension trial design including participant selection strategies to maximize enrollment of patients with true uncontrolled hypertension"

Clinical • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders

Multicenter, Randomized, Double-Blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension. (PubMed, Clin Ther) - P2 | "Low-dose triple combination therapies may be effective for treating hypertension."

Clinical • Journal • Monotherapy • P2 data • Cardiovascular • Hypertension • MID2

Low-Dose Indapamide vs. Hydrochlorothiazide in Idiopathic Hypercalciuria: A Randomized Prospective Trial. (PubMed, J Clin Med) - "No significant differences were observed between the two drugs in terms of adverse events or treatment adherence. A longer follow-up is needed to assess kidney stone recurrence."

Journal • Metabolic Disorders • Nephrology • Renal Calculi • Urolithiasis

Projected Savings for Urolithiasis Medications Purchased via Mark Cuban Cost Plus Drug Company in Medicare. (PubMed, Urol Pract) - "Using MCCPDC prices, savings were generated for all drugs at the median prices under Part D except hydrochlorothiazide and tiopronin. Depending on dosage, estimated annual savings at the median percentile prices for part D were: allopurinol $2.3-15.7 million (M), chlorthalidone $14-26M, indapamide $0.9-1.7M, penicillamine $2.3M, and potassium citrate $12.1-19.1M...DTC online pharmacies offer affordable alternatives for cash-pay customers purchasing urolithiasis medications. Replacing Part D formulary with MCCPDC pricing could yield significant savings for five generic urolithiasis medications."

Journal • Medicare • Reimbursement • US reimbursement • Nephrology • Renal Calculi • Urolithiasis

Real-World Evaluation of the Efficacy and Tolerability of a Fixed-Dose Combination of Amlodipine and Indapamide in Patients Over 55 Years. (PubMed, Cureus) - "In his real-world study, therapy was associated with substantial BP reductions, target SBP achievement, good tolerability, and improved patient-reported well-being in older adults with ISH."

HEOR • Journal • Real-world evidence • Cardiovascular • Hypertension

A Novel Stability-Indicating HPLC Method with Kinetics Study for the Concurrent Analysis of Anti-Hypertensive Drug Combination of Atenolol and Indapamide. (PubMed, Drug Metab Bioanal Lett) - "The developed stability-indicating HPLC method successfully identified and quantified atenolol and indapamide in the presence of degradation products. It offered high specificity, precision, and robustness, making it ideal for routine pharmaceutical analysis. The method distinguished between the active drugs and degradation products under various stress conditions, ensuring the long-term stability and efficacy of atenolol and indapamide formulations. These findings can significantly contribute to pharmaceutical quality control, ensuring drugs' safety and effectiveness."

Journal • Cardiovascular • Hypertension

GENOTYPE-PHENOTYPE CORRELATION IN A FAMILY WITH GORDON SYNDROME DUE TO WNK1 MUTATION (ESPN 2025) - "As a challenge, fludrocortisone was administered, TTKG remained low (1.6) thus mineralocorticoid deficiency was excluded. This suggested Gordon syndrome; hydrochlorothiazide (0.25 mg/kg/day) was started to confirm diagnosis...Indapamide, started for hypertension resolved hyperkalemia... This case and his family demonstrate that the age of onset and clinical findings vary among individuals with Gordon syndrome carrying the same mutation. Low renin and aldosterone with mild hyperkalemia, even if not accompanied by hypertension, may indicate Gordon syndrome."

Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Developmental Disorders • Endocrine Disorders • Hematological Disorders • Hypertension • Hypotension • Mental Retardation • Metabolic Disorders • Nephrology • Renal Calculi • Renal Disease • WNK1

Indapamide interference in liquid chromatography tandem mass spectrometry aldosterone assay. (PubMed, Ann Clin Biochem) - "Indapamide has been noted to cause interference in a liquid chromatography mass spectrometry method by interfering in the measurement of aldosterone-d4 internal standard. This leads to falsely increased concentrations of aldosterone which can lead to unnecessary further investigations."

Journal • Cardiovascular • Endocrine Disorders • Hypertension

Blood pressure lowering for prevention of episodic migraine: results of a pilot randomized, placebo-controlled trial of combination blood pressure lowering medication with propranolol. (PubMed, Front Neurol) - P4 | "A double-blind, randomized, pilot trial in participants with episodic migraine to assess feasibility and tolerability of low-dose triple combination BP lowering (telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25 mg) vs. propranolol 160 mg daily vs. matching placebos. The medication was safe and well tolerated by participants with migraine; it is likely that study co-design with people with lived experience of migraine will benefit recruitment into the trial. ACTRN12616000937415, https://anzctr.org.au/."

Journal • CNS Disorders • Hypotension • Migraine • Pain

TRIB3 promotes endometrial cancer progression through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis. (PubMed, Gynecol Oncol) - "TRIB3 could promote the progression of EC through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis."

Journal • Endometrial Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • E2F1 • PKM • TRIB3

Establishment and Validation of High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous Assessment of Amlodipine and Indapamide in Human Plasma. (PubMed, Rapid Commun Mass Spectrom) - "The method met validation criteria of US-FDA and EMA guidelines, thereby recommended for application in in vivo bioavailability and bioequivalence assessment of fixed-dose combinations of amlodipine with indapamide."

Journal • Cardiovascular • Hypertension

Individual patient data pooled analysis of randomised trials in Australia and United States assessing a quadruple combination single pill in patients with hypertension:results from the QUARTET studies (ESC-WCC 2025) - "Purpose: In a pre-planned analysis of these two trials, we assessed the generalisability of observed benefits and two important barriers for BP control: clinician medication inertia and patient medication adherence. Both QUARTET trials were randomised, multicentre, double-blinded trials in people with hypertension ≤1 medication, comparing a quadpill containing 37·5mg of irbesartan (2mg candesartan in US), 1·25mg of amlodipine, 0·625mg of indapamide, and 2·5mg of bisoprolol with initial monotherapy (150mg of irbesartan in Australia, 8mg of candesartan in US). This prospective individual participant data pooled analysis provides further evidence that the quadpill strategy is superior to usual care, with improved efficacy despite much lower up titration rates."

Retrospective data • Cardiovascular • Hypertension

Molecular mechanisms of thiazide-like diuretics-mediated inhibition of the human Na-Cl cotransporter. (PubMed, Nat Commun) - "To understand the molecular mechanisms of NCC inhibition by thiazide-like diuretics, we determine the structures of human NCC (hNCC) bound to two of the most widely used thiazide-like diuretics, chlorthalidone and indapamide, using cryogenic electron microscopy (cryo-EM). Furthermore, structural comparisons allow us to identify polymorphisms in hNCC that have substantial differential effects on the potencies of specific thiazide-like and thiazide-type diuretics. Our work provides important insights into the molecular pharmacology of NCC and a blueprint for developing precision medicine to manage hypertension with thiazide-like and thiazide-type diuretics."

Journal • Cardiovascular • Hypertension

Dispensing practices issue shorter prescription lengths compared to non-dispensing practices. (PubMed, BJGP Open) - "Dispensing practices are associated with shorter prescription lengths, increasing the number of prescriptions issued over time and the associated dispensing fee. The absence of clear guidance on prescription lengths likely contributes to this-central bodies should consider providing explicit recommendations to optimise prescription durations."

Journal

Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional Study. (PubMed, Endocr Metab Immune Disord Drug Targets) - "Regular monitoring of serum magnesium may aid in identifying at-risk patients, especially those with hypertension, CHF, or on magnesium-depleting medications. Further prospective studies are needed to clarify the clinical utility of magnesium in diabetes care."

Journal • Observational data • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database. (PubMed, Epilepsy Behav) - "This study provides real-world evidence on the epidemiological characteristics, age-related drug risk heterogeneity, and early-onset patterns of DRES. It highlights the need for individualized pharmacovigilance and regulatory updates to address under-recognized neurotoxic risks, particularly in vulnerable age groups. These findings contribute critical insights into safer prescribing practices and improved post-marketing surveillance."

Journal • Real-world evidence • CNS Disorders • Epilepsy • Oncology

HYPOCARE treat: Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism (clinicaltrials.gov) - P4 | N=24 | Recruiting | Sponsor: Lars Rejnmark

New P4 trial • Endocrine Disorders • Hypoparathyroidism

Optimizing Nephron Performance: The Old, the New, and the New-Old Diuretic Therapies. (PubMed, Biomedicines) - "However, the efficacy of these agents and indapamide, a slightly newer but still "old" diuretic in preventing blood pressure-related cardiovascular disease, has been demonstrated in randomized controlled trials...Chlorthalidone had a large blood-pressure-lowering effect in patients with stage IV CKD. Acetazolamide was effective in accelerating the clinical control of patients with acute heart failure, including patients with some reduction in kidney function. We anticipate investigating the comparative impact of combining different agents to optimize nephron function in the future."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study. (PubMed, BMJ Med) - "In an exploratory secondary analysis, sustained treatment with modified release preparations was associated with a lower the risk of cardiovascular events but not all cause mortality compared with immediate release preparations. These findings need to be confirmed in prospective studies."

HEOR • Journal • Cardiovascular • Hypertension • Myocardial Infarction

Indapamide or chlorthalidone to reduce urine supersaturation for secondary prevention of kidney stones: protocol for a randomised, double-blind, cross-over trial (INDAPACHLOR). (PubMed, BMJ Open) - P2 | "This clinical routine has recently been challenged by the findings of the large NOSTONE trial that failed to show superiority of hydrochlorothiazide at doses up to 50 mg daily over placebo in preventing a composite of clinical or radiological recurrence in patients at high risk of kidney stone recurrence. ClinicalTrials.gov (NCT06111885) and Swiss National Clinical Trials Portal (SNCTP000006156). Version 4.0, 29 November 2024."

Clinical • Clinical protocol • Journal • Nephrology • Renal Calculi • Urolithiasis • Urology